Axial Spondyloarthritis – Landscape & Forecast – Disease Landscape & Forecast

Copy/Paste the key inputs from the product brochure, per guidance from Marketing.

The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the blockbuster tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s Humira, Janssen’s Remicade and Simponi / Simponi Aria, and UCB’s Cimzia) and two IL-17 inhibitors (Novartis’s Cosentyx and Eli Lilly’s Taltz). The TNF-α inhibitors are the most widely prescribed biologics in AxSpA patients refractory to nonsteroidal anti-inflammatory drugs (NSAIDs). However, these agents face a competitive threat, both from the launch of cost-effective biosimilars and the growing IL-17 class, which has efficacy data that have met more-stringent clinical trial endpoints. Cimzia was approved by the FDA in 2019 for nonradiographic (nr)-AxSpA, marking the first FDA approval for that subpopulation, followed by Cosentyx and Taltz in June 2020. The impending entry of additional IL-17 inhibitors (UCB’s bimekizumab and Kyowa Hakko Kirin’s Lumicef) and the first oral targeted therapies—Jak inhibitors—for this indication (Pfizer’s Xeljanz and AbbVie's Rinvoq) will also shift market dynamics.

Questions answered:

  • How large is the treatable AxSpA population, and how will diagnosis / drug-treatment rates change over time?
  • What are interviewed experts’ insights on current treatment options for ankylosing spondylitis (AS) and nr-AxSpA? What clinical needs remain unfulfilled?
  • What pipeline products are the most promising, and what sales / uptake could they secure in AxSpA? What therapies of note are progressing in earlier phases?
  • What are the drivers and constraints in the AxSpA market, and how will the market evolve over the forecast period?

Content highlights:

Geographies: United States, EU5, Japan

Primary Research: ~30 country-specific interviews with thought-leading rheumatologists; Supported by survey data collected for this and other DRG research

Epidemiology: Diagnosed prevalent cases of axial spondyloarthritis by country, ankylosing spondylitis and nonradiographic axial spondyloarthritis subpopulations

Forecast: 10-year, annualized, drug-level sales and patient share of key axial spondyloarthritis therapies through 2029, segmented by brands/generics and epidemiological subpopulations

Emerging therapies: Phase III: 4 drugs; Phase II: 1 drugs

Product description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement:​​​​​​

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Axial Spondyloarthritis - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q4 2021
        • October 2021
      • Q3 2021
        • August 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • December 2020
    • Key Findings
      • Market Outlook
        • Key Findings
          • Market Share of Drug Classes for Axial Spondyloarthritis: 2020
          • Market Share of Drug Classes for Axial Spondyloarthritis: 2030
          • Axial Spondyloarthritis SWOT Analysis
        • Market Drivers and Constraints
          • What Factors Are Driving the Market for Axial Spondyloarthritis?
          • What Factors Are Constraining the Market for Axial Spondyloarthritis?
        • Drug-Class Specific Trends
          • Major-Market Sales of NSAIDs for Axial Spondyloarthritis by Drug Class
          • Major-Market Sales of TNF-Alpha Inhibitors for Axial Spondyloarthritis
          • Major-Market Sales of Branded and Biosimilar TNF-Alpha Inhibitors
          • Sales of TNF-Alpha Inhibitors for Axial Spondyloarthritis by Market Segment
          • Major-Market Sales of IL-17 Inhibitors for Axial Spondyloarthritis
          • Sales of IL-17 Inhibitors for Axial Spondyloarthritis by Market Segment
          • Sales of JAK Inhibitors for Axial Spondyloarthritis by Market Segment
      • Forecast
        • Market Forecast Assumptions - Axial Spondyloarthritis (2020-2030) - October 2021
        • Market Forecast Dashboards - Axial Spondyloarthritis (2020-2030) - October 2021
      • Etiology and Pathophysiology
        • Disease Overview
          • Classification Criteria in Axial Spondyloarthritis
            • Systems Used to Classify Axial Spondyloarthritis
          • Presentation and Disease Progression
            • Key Pathways and Drug Targets
              • Pathways Involved in Inflammation and Bone Damage in Axial Spondyloarthritis
          • Epidemiology
            • Key Findings
              • Epidemiology Populations
                • Disease Definition
                • Methods
                • Sources Used for Total Prevalent Cases of Axial Spondyloarthritis
                • Number of Total Prevalent Cases of Axial Spondyloarthritis in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
                • Disease Definition
                • Methods
                • Sources Used for Total Prevalence of Ankylosing Spondylitis
                • Total Prevalent Cases of Ankylosing Spondylitis in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
                • Disease Definition
                • Methods
                • Sources Used for Total Prevalent Cases of Nonradiographic Axial Spondyloarthritis
                • Total Prevalent Cases of Nonradiographic Axial Spondyloarthritis in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
                • Disease Definition
                • Methods
                • Sources Used for Total Prevalent Cases of Axial Spondyloarthritis by HLA-B27 Status
                • HLA-B27-Positive Cases in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
                • Diagnosed Prevalent Cases of Axial Spondyloarthritis: 2020-2030 (Thousands)
                • Drug-Treated Prevalent Cases of Axial Spondyloarthritis: 2020-2030 (Thousands)
            • Current Treatment
              • Key Findings
                • Treatment Goals
                  • Key Endpoints Used in Clinical Trials for Axial Spondyloarthritis
                • Key Current Therapies
                  • Overview
                  • Mechanism of Action of Key Current Drug Classes Used for Axial Spondyloarthritis
                  • Current Treatments Used for Axial Spondyloarthritis
                  • Market Events Impacting the Use of Key Current Therapies for Axial Spondyloarthritis
                  • Advantages and Disadvantages of NSAIDs
                  • Expert Insight: NSAIDs
                  • Advantages and Disadvantages of Conventional DMARDs
                  • Expert Insight: Conventional DMARDs
                  • Advantages and Disadvantages of Adalimumab
                  • Expert Insight: Adalimumab
                  • Advantages and Disadvantages of Etanercept
                  • Expert Insight: Etanercept
                  • Advantages and Disadvantages of Infliximab
                  • Expert Insight: Infliximab
                  • Advantages and Disadvantages of Simponi
                  • Expert Insight: Simponi
                  • Advantages and Disadvantages of Cimzia
                  • Expert Insight: Cimzia
                  • Advantages and Disadvantages of Cosentyx
                  • Ongoing Clinical Development of Cosentyx
                  • Key Ongoing Clinical Trials of Cosentyx in the Treatment of Axial Spondyloarthritis
                  • Expert Insight: Cosentyx
                  • Taltz
                  • Advantages and Disadvantages of Taltz
                  • Ongoing Clinical Development of Taltz
                  • Key Ongoing Clinical Trials of Taltz in the Treatment of Axial Spondyloarthritis
                  • Expert Insight: Taltz
                  • Rinvoq
                  • Advantages and Disadvantages of Rinvoq
                  • Ongoing Clinical Development of Rinvoq
                  • Key Ongoing Clinical Trials of Rinvoq in the Treatment of AxSpA
                  • Expert Insight: Rinvoq
                • Medical Practice
                  • Overview
                  • Factors Influencing Drug Selection in Axial Spondyloarthritis
                  • Treatment Decision Tree for Axial Spondyloarthritis: United States
                  • Treatment Decision Tree for Axial Spondyloarthritis: Europe
                  • Treatment Decision Tree for Axial Spondyloarthritis: Japan
              • Unmet Need Overview
                • Current and Future Attainment of Unmet Needs in Axial Spondyloarthritis
                • Top Unmet Needs in Axial Spondyloarthritis: Current and Future Attainment
                • Expert Insight: Unmet Need in Axial Spondyloarthritis
              • Emerging Therapies
                • Key Findings
                  • Key Emerging Therapies
                    • Key Therapies in Development for Axial Spondyloarthritis
                    • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Axial Spondyloarthritis
                    • Bimekizumab Profile
                    • Key Ongoing Clinical Trials of Bimekizumab in the Treatment of AxSpA
                    • Analysis of the Clinical Development Program for Bimekizumab
                    • Expert Insight: Bimekizumab
                    • Expectations for Launch and Sales Opportunity of Bimekizumab in Axial Spondyloarthritis
                    • Lumicef Profile
                    • Analysis of the Clinical Development Program for Lumicef
                    • Expert Insight: Lumicef
                    • Expectations for Launch and Sales Opportunity of Lumicef in Axial Spondyloarthritis
                    • Xeljanz Profile
                    • Analysis of the Clinical Development Program for Xeljanz
                    • Expert Insight: Xeljanz
                    • Expectations for Launch and Sales Opportunity of Xeljanz in Axial Spondyloarthritis
                  • Early-Phase Pipeline Analysis
                    • Select Compounds in Phase II Development for Axial Spondyloarthritis
                • Access & Reimbursement Overview
                  • Region-Specific Reimbursement Practices
                    • Key Market Access Considerations in Axial Spondyloarthritis: United States
                    • General Reimbursement Environment: United States
                    • Key Market Access Considerations in Axial Spondyloarthritis: EU5
                    • General Reimbursement Environment: EU5
                    • Key Market Access Considerations in Axial Spondyloarthritis: Japan
                    • General Reimbursement Environment: Japan
                • Appendix
                  • Axial Spondyloarthritis Bibliography